comparemela.com

Latest Breaking News On - Myokardia inc - Page 9 : comparemela.com

Fast heart, slow heart: Changes in the molecular motor myosin explain the difference

 E-Mail The human heart contracts about 70 times per minute, while that of a rat contracts over 300 times; what accounts for this difference? In a new study publishing 10th June in the open-access journal PLOS Biology, led by Michael Geeves and Mark Wass of the University of Kent and Leslie Leinwand from the University of Colorado Boulder, reveal the molecular differences in the heart muscle protein beta myosin that underly the large difference in contraction velocity between the two species. Myosin is a molecular motor - an intricate nanomachine that forms the dynamic core of a muscle s contractile machinery, burning cellular chemical energy in the form of ATP to rapidly and reversibly exert force against cables of actin. In so doing, it pulls the ends of the muscle cell closer together, causing muscle contraction. It has long been known that the maximal rate of contraction, called V0, varies predictably among mammals: In small mammals with their high metabolic rate, V0 is hi

EXPLORER-HCM Trial finds substantial health status improvements with mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM)

EXPLORER-HCM Trial finds substantial health status improvements with mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) Share Article Saint Luke s Mid America Heart Institute shared trial findings at American College of Cardiology’s 2021 Scientific Session The benefits observed were amongst the largest we have ever seen from a medication to improve the symptoms, function and quality of life of patients with heart failure. KANSAS CITY, Mo. (PRWEB) May 20, 2021 The EXPLORER-HCM (Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy) Randomized Clinical Trial has shown significant improvement in the symptoms, function, and quality of life in patients with obstructive hypertrophic cardiomyopathy (oHCM) with taking mavecamten. This comes following no major advances for treating oHCM in more than 30 years, where the primary goals of treat

Genentech, Myokardia veterans look to create new playbook against autoimmune diseases with $70M from Foresite Capital

Genentech, Myokardia veterans look to create new playbook against autoimmune diseases with $70M from Foresite Capital
bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.

Former Genentech execs, including ex-CEO Ian Clark, jump in with IPO-seeking gene therapy company Gyroscope

Former Genentech execs, including ex-CEO Ian Clark, jump in with IPO-seeking gene therapy company Gyroscope
bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.

Former Genentech execs, including ex-CEO Ian Clark, jump in with IPO-seeking gene therapy company Gyroscope

Former Genentech execs, including ex-CEO Ian Clark, jump in with IPO-seeking gene therapy company Gyroscope
bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.